RA Capital Management has led a series B round for the UW-linked vaccine developer, which had raised $51m in a series A 18 months ago.
Icosavax, a US-based vaccine developer exploiting research from University of Washington (UW) completed a $100m series B round yesterday led by investment manager RA Capital Management.
Pharmaceutical firm Sanofi’s strategic investment arm, Sanofi Ventures, also took part, as did Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, Open Philanthropy and Surveyor Capital.
Qiming Venture Partners USA, Adams Street Partners and ND Capital (formerly known as NanoDimension) filled out the round, having joined Sanofi…
